Development of treatment and clinical results in childhood acute myeloid leukemia in the Czech Republic

被引：3

作者：

Sramkova L. ^{[1
]}

Sterba J. ^{[2
]}

Hrstkova H. ^{[3
]}

Mihal V. ^{[4
]}

Blazek B. ^{[5
]}

Timr P. ^{[6
]}

Cerna Z. ^{[7
]}

Prochazkova D. ^{[8
]}

Hak J. ^{[9
]}

Sedlacek P. ^{[1
]}

Janotova I. ^{[1
]}

Vodickova E. ^{[10
]}

Zemanova Z. ^{[11
]}

Jarosova M. ^{[12
]}

Oltova A. ^{[13
]}

Zdrahalova K. ^{[1
]}

Hrusak O. ^{[1
]}

Mejstrikova E. ^{[1
]}

Schwarz J. ^{[14
]}

Zuna J. ^{[1
]}

Trka J. ^{[1
]}

Stary J. ^{[1
]}

机构：

[1] Department of Pediatric Hematology and Oncology, 2nd Medical School, Charles University Prague, Prague

[2] Department of Pediatric Oncology, University Hospital Brno, Brno

[3] Pediatric Department, University Hospital Brno, Brno

[4] Pediatric Department, University Hospital Olomouc, Olomouc

[5] Pediatric Department, University Hospital, Ostrava-Poruba

[6] Pediatric Department, Hospital Ceske Budejovice, Ceske Budejovice

[7] Pediatric Department, University Hospital, Plzen

[8] Pediatric Department, Masaryk's Hospital, Usti nad Labem

[9] Pediatric Department, University Hospital, Hradec Kralove

[10] Department of Clinical Hematology, University Hospital, Prague

[11] Center of Tumor Cytogenetics, 1st Medical School, Charles University Prague, Prague

[12] Department of Hematooncology, University Hospital Olomouc, Olomouc

[13] Department of Medical Genetics, University Hospital Brno, Brno

[14] Institute of Hematology and Blood Transfusion, Prague

来源：

memo - Magazine of European Medical Oncology | 2013年 / 6卷 / 1期

关键词：

Acute myeloid leukemia; AML-BFM; 2004; 93; 98; Children; Czech Republic;

D O I：

10.1007/s12254-012-0059-3

中图分类号：

学科分类号：

摘要：

Purpose: Treatment of childhood acute myeloid leukemia (AML) was unified in the year 1993 according to acute myeloid leukemia-Berlin-Frankfurt-Munster (AML-BFM) protocols in the Czech Republic. We evaluated data on clinical and therapeutic results in children with AML treated in three subsequent trials, comparing two periods, June 1993 to February 2004 (AML-BFM 93 and 98) vs. March 2004 to December 2009 (AML-BFM 2004 trial). Patients and methods: Data of 182 eligible patients were analyzed, 125 in AML-BFM 93 and 98 trials, and 57 in AML-BFM 2004 trial enrolled prior to December 2009. Down syndrome patients were excluded from analysis. Results: In studies AML-BFM 93 and 98, 79.2 % of 125 patients achieved complete remission (CR), 19 patients (15.2 %) suffered from early death, 7 (5.6 %) were nonresponders, 33 (33.3 %) relapsed, 12 (12.1 %) died in CR, and 2 patients (2.0 %) developed secondary malignancy. The estimated probability of event-free survival (pEFS) at 5 years was 41.6 %, the overall survival (OS) at 5 years was 46.4 %. In AML-BFM 2004 trial, 93 % of 57 patients attained CR, 3 patients (5.2 %) suffered from early death, 1 (1.8 %) was nonresponder, 16 (30.2 %) relapsed, 2 (3.8 %) died in CR, and 2 patients (3.5 %) developed secondary malignancy. The estimated pEFS at 5 years was 56.1 %, 5-years overall survival (5y-OS) was 73.7 %. Conclusion: Gradual improvement of CR rate and OS together with decreasing incidence of toxic deaths in AML patients were achieved because of gain of experience with very intensive modern treatment centralized in a limited number of institutions. © 2012 Springer-Verlag Wien.

引用

页码：41 / 45

页数：4

共 20 条

[1]

Stary J., Gajdos P., Blazek B., Ptoszkova H., Hrstkova H., Kopecna L., Tousovska K., Hak J., Prochazkova D., Cerna Z., Jabali Y., Timr P., Vavra V., Sedlacek P., Smisek P., Hrusak O., Michalova K., Sjednocení Léc by Detí s Akutní Myeloidní Leukémií v Ceské Republice Podle Protokolu AML-BFM 93, Casopis Lekaru Ceskych, 143, 4, pp. 257-263, (2004)

[2]

Stary J., Vavra V., Gajdos P., Second national study AML-BFM 98 improved remission rate and overall survival in children with acute myeloid leukemia in the Czech Republic, Trans Hemat Dnes, 14, pp. 166-174, (2008)

[3]

Bennett J.M., Catovsky D., Daniel M.T., Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British Cooperative Group, Ann Intern Med., 103, pp. 620-625, (1985)

[4]

Bennett J.M., Catovsky D., Daniel M.T., Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0), Br J Haematol., 78, pp. 325-329, (1991)

[5]

Bennett J.M., Catovsky D., Daniel M.-T., Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group, Annals of Internal Medicine, 103, 3, pp. 460-462, (1985)

[6]

Rubnitz J.E., Raimondi S.C., Tong X., Kumar Srivastava D., Razzouk B.I., Shurtleff S.A., Downing J.R., Pui C.-H., Ribeiro R.C., Behm F.G., Favorable impact of the t(9

[7]

11) in childhood acute myeloid leukemia, Journal of Clinical Oncology, 20, 9, pp. 2302-2309, (2002)

[8]

Balgobind B.V., Raimondi S.C., Harbott J., Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: Results of an international retrospective study, Blood., 114, pp. 2489-2496, (2009)

[9]

Casillas J.N., Woods W.G., Hunger S.P., McGavran L., Alonzo T.A., Feig S.A., Prognostic implications of t(10

[10]

11) translocations in childhood acute myelogenous leukemia: A report from the Children's Cancer Group, Journal of Pediatric Hematology/Oncology, 25, 8, pp. 594-600, (2003)

← 1 2 →